BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16198987)

  • 1. Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib.
    Savani BN; Srinivasan R; Espinoza-Delgado I; Dorrance C; Takahashi Y; Igarashi T; Rezvani K; Lundqvist A; Barrett AJ; Childs RW
    Lancet Oncol; 2005 Oct; 6(10):809-12. PubMed ID: 16198987
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
    Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
    Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib.
    Breccia M; Capria S; Iori AP; Foà R; Alimena G; Meloni G
    Acta Haematol; 2010; 124(3):150-2. PubMed ID: 20938169
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome.
    Jin Huh H; Won Huh J; Myong Seong C; Lee M; Soon Chung W
    Am J Hematol; 2003 Nov; 74(3):218-20. PubMed ID: 14587058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive chemotherapy and autologous hematopoietic stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast crisis chronic myeloid leukaemia.
    Heim D; Friess D; Christen S; Stüssi G; Meyer-Monard S; Tichelli A; Passweg JR; Gratwohl A
    Leukemia; 2006 May; 20(5):898-900. PubMed ID: 16525490
    [No Abstract]   [Full Text] [Related]  

  • 6. [Efficacies of hematopoietic stem cell transplantation plus imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparative study].
    Chen J; Wu DP; Chen F; Zhao Y; Sun AN; Qiu HY
    Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(8):583-7. PubMed ID: 23663336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.
    Kawano N; Okuda S; Yoshida S; Kugimiya H; Ito M; Horikawa N; Chosa N; Hisakata T; Fukudome T; Sakurai R; Yamashita K; Ueda A; Kanda Y
    Int J Hematol; 2011 Dec; 94(6):561-6. PubMed ID: 22057509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
    Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib for relapsed BCR/ABL positive leukemias.
    Ottmann OG; Wassmann B; Hoelzer D
    Ann Hematol; 2002; 81 Suppl 2():S36-7. PubMed ID: 12611069
    [No Abstract]   [Full Text] [Related]  

  • 11. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).
    Schiffer CA; Hehlmann R; Larson R
    Leukemia; 2003 Apr; 17(4):691-9. PubMed ID: 12682626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords.
    Swords R
    Drugs; 2007; 67(17):2655-6. PubMed ID: 18034599
    [No Abstract]   [Full Text] [Related]  

  • 15. [Outcome of autologous hematopoietic stem cell transplantation in combination with imatinib for 16 cases of Philadelphia chromosome positive acute lymphoblastic leukemia].
    Liu X; Jiang E; Huang Y; Yang D; Pang A; Wei J; Ma Q; Zhang R; Qiu L; Feng S; Han M
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):250-2. PubMed ID: 24666497
    [No Abstract]   [Full Text] [Related]  

  • 16. Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure.
    O'Connor LM; Langabeer S; McCann SR; Conneally E
    Bone Marrow Transplant; 2008 Dec; 42(12):833-5. PubMed ID: 18711344
    [No Abstract]   [Full Text] [Related]  

  • 17. [Allogeneic hematopoietic stem cell transplantation combined with imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia].
    Cai B; Gao CJ; Li HH; Bo J; Huang WR; Gao L; Sun JF; Ding Y; Wang LL; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):173-6. PubMed ID: 20137141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib.
    Tiribelli M; Sperotto A; Candoni A; Simeone E; Buttignol S; Fanin R
    Leuk Res; 2009 Jan; 33(1):174-7. PubMed ID: 18471874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion.
    Tachibana T; Numata A; Tanaka M; Motohashi K; Fujisawa S; Fujita H; Sakai R; Tomita N; Maruta A; Ishigatsubo Y; Kanamori H
    Leuk Lymphoma; 2011 Jul; 52(7):1376-9. PubMed ID: 21438838
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term durability of molecular and chimerism responses in patients treated with imatinib for chronic myeloid leukemia relapse after allogeneic transplantation.
    Martín-Palanco V; Martínez F; Arqueros V; Torres A; Román-Gómez J
    Eur J Haematol; 2011 Aug; 87(2):182-5. PubMed ID: 21762210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.